A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)C. Papayannidis, C. DiNardo,P. Montesinos,A. Schuh,P. Vyas,A. Wei,H. Ommen,S. Semochkin, H. Kim, R. Larson, J. Koprivnikar, O. Frankfurt, F. Thol, J. Chromik,J. Byrne,A. Pigneux, X. Thomas,O. Salamero,M. Vidriales, V. Doronin,H. Dohner,A. Fathi, E. Laille, X. Yu, M. Hasan, P. Martin-Regueira,S. de BottonHAEMATOLOGICA（2021）引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
